Clinical-development physician must resolve whether scientific advice should

Situation

Clinical-development physician in a company with a CMC site change mid-review has one working extract — advisory-committee question list that exposes a weak secondary endpoint — after a pediatric ethicist objecting to the proposed design. If advisory-committee question list that exposes a weak secondary endpoint cannot support scientific advice should be, the honest Pharma & Life Sciences output is hold.

Decision

Clinical-development physician in a company with a CMC site change mid-review must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using advisory-committee question list that exposes a weak secondary endpoint after a pediatric ethicist objecting to the proposed design.

Hypotheses to test

• The population in advisory-committee question list that exposes a weak secondary endpoint is the one a pediatric ethicist objecting to the proposed design named, so Proceed under protocol follows for this FDA Response and Labeling file.
• The population in advisory-committee question list that exposes a weak secondary endpoint is adjacent only to a pediatric ethicist objecting to the proposed design; Pause the pathway is the honest Pharma & Life Sciences call.
• A company with a CMC site change mid-review already contained a pediatric ethicist objecting to the proposed design before advisory-committee question list that exposes a weak secondary endpoint arrived; no new FDA Response and Labeling path.
• Provenance on advisory-committee question list that exposes a weak secondary endpoint after a pediatric ethicist objecting to the proposed design is broken; do not pick Proceed under protocol or Pause the pathway yet.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in advisory-committee question list that exposes a weak secondary endpoint after a pediatric ethicist objecting to the proposed design.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on scientific advice should be.
• For this Pharma & Life Sciences FDA Response and Labeling file, read advisory-committee question list that exposes a weak secondary endpoint against a pediatric ethicist objecting to the proposed design and write the one fact that would move scientific advice should be for clinical-development physician.